News Posts List
The prognostic factors for patients with pT1a renal cell carcinoma
05/20/2010
Although the prognosis of patients with pT1a stage renal cell carcinoma (RCC) is generally good, some of these patients show distant metastasis. In this study, we intended to identify the perioperative and pathologic prognostic factors for patients with pT1a stage RCC.
Genetic Secrets of Common Kidney Cancer
05/19/2010
By examining expression of every human gene in clear cell renal cell carcinoma (ccRCC) compared to normal kidney cells, researchers at Mayo Clinic's campus in Florida have discovered gene signatures they say explain much of the biology of this common and difficult-to-treat kidney cancer.
Renal Cancer Project ANYARA Featured in Journal of Immunotherapy
05/19/2010
The results show that critical properties of ANYARA (naptumomab estafenatox), such as tumor reactivity and therapeutic window were improved.
Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?
05/19/2010
The authors conducted a retrospective study to investigate the overall survival (OS) of patients who underwent CN using the OS of patients with mRCC who did not undergo CN as a referent group.
Immutep announces oral presentation at ASCO Annual Meeting of IMP321 final results in Phase I/II chemoimmunotherapy trial
05/19/2010
A Phase I trial in metastatic renal cell carcinoma with IMP321 alone has been completed.
Wilex German Biotech Meets FDA Phase 3 Endpoints for Renal Cancer Diagnosis
05/19/2010
Based on these results, WILEX plans to submit REDECTANE® for approval by the US Food and Drug Administration (FDA) at the end of 2010.
Management of side effects associated with antiangiogenic treatment in renal cell carcinoma
05/19/2010
Clinicians have changed their practice and are faced with a number of new adverse events.
Cancer drug policy has shocking flaws
05/19/2010
Is an overstretched and underfunded National Health Service to blame?
Kidney removal studied in kidney cancer
05/18/2010
A Cleveland Clinic study suggests the removal of cancerous kidneys does not prolong the lives of patients 75 years or older.
American Cancer Society awards 152 new research and training grants
05/18/2010
Dr. Wendy Rathmell at the University of North Carolina has detected a novel protein, Ror2 which is abundant in renal cell tumors, particularly those with a very poor prognosis. Dr. Robert Huigens working at the University of Illinois is attempting to make the natural product, Englerin A, which was isolated in tiny quantities from a plant in Africa. Englerin A has generated excitement for showing highly potent and selective activity for elimination of renal cancer cells.
News Feed